Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.

Lewis M, Mori J, Toma J, Mosley M, Huang W, Simpson P, Mansfield R, Craig C, van der Ryst E, Robertson DL, Whitcomb JM, Westby M.

PLoS One. 2018 Dec 26;13(12):e0204099. doi: 10.1371/journal.pone.0204099. eCollection 2018.

2.

Prevalence of Darunavir Resistance in the United States from 2010 to 2017.

Brown K, Stewart L, Whitcomb JM, Yang D, Nettles RE, Lathouwers E.

AIDS Res Hum Retroviruses. 2018 Dec;34(12):1036-1043. doi: 10.1089/AID.2018.0100. Epub 2018 Oct 31.

3.

Detailed Transmission Network Analysis of a Large Opiate-Driven Outbreak of HIV Infection in the United States.

Campbell EM, Jia H, Shankar A, Hanson D, Luo W, Masciotra S, Owen SM, Oster AM, Galang RR, Spiller MW, Blosser SJ, Chapman E, Roseberry JC, Gentry J, Pontones P, Duwve J, Peyrani P, Kagan RM, Whitcomb JM, Peters PJ, Heneine W, Brooks JT, Switzer WM.

J Infect Dis. 2017 Nov 27;216(9):1053-1062. doi: 10.1093/infdis/jix307.

4.

A decade of HIV-1 drug resistance in the United States: trends and characteristics in a large protease/reverse transcriptase and co-receptor tropism database from 2003 to 2012.

Paquet AC, Solberg OD, Napolitano LA, Volpe JM, Walworth C, Whitcomb JM, Petropoulos CJ, Haddad M.

Antivir Ther. 2014;19(4):435-41. doi: 10.3851/IMP2748. Epub 2014 Feb 12.

PMID:
24518099
5.

Estimating the fitness cost of escape from HLA presentation in HIV-1 protease and reverse transcriptase.

Mostowy R, Kouyos RD, Hoof I, Hinkley T, Haddad M, Whitcomb JM, Petropoulos CJ, Keşmir C, Bonhoeffer S.

PLoS Comput Biol. 2012;8(5):e1002525. doi: 10.1371/journal.pcbi.1002525. Epub 2012 May 24.

6.

Exploring the complexity of the HIV-1 fitness landscape.

Kouyos RD, Leventhal GE, Hinkley T, Haddad M, Whitcomb JM, Petropoulos CJ, Bonhoeffer S.

PLoS Genet. 2012;8(3):e1002551. doi: 10.1371/journal.pgen.1002551. Epub 2012 Mar 8.

7.

Assessing predicted HIV-1 replicative capacity in a clinical setting.

Kouyos RD, von Wyl V, Hinkley T, Petropoulos CJ, Haddad M, Whitcomb JM, Böni J, Yerly S, Cellerai C, Klimkait T, Günthard HF, Bonhoeffer S; Swiss HIV Cohort Study.

PLoS Pathog. 2011 Nov;7(11):e1002321. doi: 10.1371/journal.ppat.1002321. Epub 2011 Nov 3.

8.

Connecticut's enhanced care clinic initiative: early returns from pediatric-behavioral health partnerships.

Pidano AE, Marcaly KH, Ihde KM, Kurowski EC, Whitcomb JM.

Fam Syst Health. 2011 Jun;29(2):138-43. doi: 10.1037/a0023474.

PMID:
21517176
9.

A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase.

Hinkley T, Martins J, Chappey C, Haddad M, Stawiski E, Whitcomb JM, Petropoulos CJ, Bonhoeffer S.

Nat Genet. 2011 May;43(5):487-9. doi: 10.1038/ng.795. Epub 2011 Mar 27.

PMID:
21441930
10.

Principal component analysis of general patterns of HIV-1 replicative fitness in different drug environments.

Martins JZ, Chappey C, Haddad M, Whitcomb JM, Stawiski E, Petropoulos CJ, Bonhoeffer S.

Epidemics. 2010 Jun;2(2):85-91. doi: 10.1016/j.epidem.2010.03.003. Epub 2010 Mar 31.

PMID:
21352778
11.

Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.

Toma J, Weinheimer SP, Stawiski E, Whitcomb JM, Lewis ST, Petropoulos CJ, Huang W.

J Virol. 2011 Apr;85(8):3872-80. doi: 10.1128/JVI.02237-10. Epub 2011 Feb 2.

12.

Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.

Larson JS, Goodman LJ, Tan Y, Defazio-Eli L, Paquet AC, Cook JW, Rivera A, Frankson K, Bose J, Chen L, Cheung J, Shi Y, Irwin S, Kiss LD, Huang W, Utter S, Sherwood T, Bates M, Weidler J, Parry G, Winslow J, Petropoulos CJ, Whitcomb JM.

Patholog Res Int. 2010 Jun 28;2010:814176. doi: 10.4061/2010/814176.

13.

Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1.

Huang W, Frantzell A, Toma J, Fransen S, Whitcomb JM, Stawiski E, Petropoulos CJ.

Virology. 2011 Jan 20;409(2):308-18. doi: 10.1016/j.virol.2010.09.026. Epub 2010 Nov 10.

14.

Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors.

Toma J, Whitcomb JM, Petropoulos CJ, Huang W.

AIDS. 2010 Sep 10;24(14):2181-6. doi: 10.1097/QAD.0b013e32833c543f.

PMID:
20639728
15.

Psychometric properties of the Coolidge Correctional Inventory in a sample of 3,962 prison inmates.

Coolidge FL, Segal DL, Klebe KJ, Cahill BS, Whitcomb JM.

Behav Sci Law. 2009 Sep-Oct;27(5):713-26. doi: 10.1002/bsl.896.

PMID:
19784941
16.

Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals.

Huang W, Toma J, Stawiski E, Fransen S, Wrin T, Parkin N, Whitcomb JM, Coakley E, Hecht FM, Deeks SG, Gandhi RT, Eshleman SH, Petropoulos CJ.

AIDS Res Hum Retroviruses. 2009 Aug;25(8):795-802. doi: 10.1089/aid.2008.0252.

17.

Vertical transmission of X4-tropic and dual-tropic HIV-1 in five Ugandan mother-infant pairs.

Huang W, Eshleman SH, Toma J, Stawiski E, Whitcomb JM, Jackson JB, Guay L, Musoke P, Parkin N, Petropoulos CJ.

AIDS. 2009 Sep 10;23(14):1903-8. doi: 10.1097/QAD.0b013e32832f1802.

18.

Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.

Fransen S, Bridger G, Whitcomb JM, Toma J, Stawiski E, Parkin N, Petropoulos CJ, Huang W.

Antimicrob Agents Chemother. 2008 Jul;52(7):2608-15. doi: 10.1128/AAC.01226-07. Epub 2008 Apr 28.

19.

Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein.

Huang W, Toma J, Fransen S, Stawiski E, Reeves JD, Whitcomb JM, Parkin N, Petropoulos CJ.

J Virol. 2008 Jun;82(11):5584-93. doi: 10.1128/JVI.02676-07. Epub 2008 Mar 19.

20.

Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.

Huang W, Eshleman SH, Toma J, Fransen S, Stawiski E, Paxinos EE, Whitcomb JM, Young AM, Donnell D, Mmiro F, Musoke P, Guay LA, Jackson JB, Parkin NT, Petropoulos CJ.

J Virol. 2007 Aug;81(15):7885-93. Epub 2007 May 16.

21.

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.

Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ.

Antimicrob Agents Chemother. 2007 Feb;51(2):566-75. Epub 2006 Nov 20.

22.

HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia.

Spudich SS, Huang W, Nilsson AC, Petropoulos CJ, Liegler TJ, Whitcomb JM, Price RW.

J Infect Dis. 2005 Mar 15;191(6):890-8. Epub 2005 Feb 9.

PMID:
15717264
23.

Assessing chemokine co-receptor usage in HIV.

Coakley E, Petropoulos CJ, Whitcomb JM.

Curr Opin Infect Dis. 2005 Feb;18(1):9-15. Review.

PMID:
15647694
24.

Evidence for positive epistasis in HIV-1.

Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ.

Science. 2004 Nov 26;306(5701):1547-50. Erratum in: Science. 2008 May 9;320(5877):746.

25.

Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine.

Uhlmann EJ, Tebas P, Storch GA, Powderly WG, Lie YS, Whitcomb JM, Hellmann NS, Arens MQ.

J Clin Virol. 2004 Nov;31(3):198-203.

PMID:
15465412
26.

Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.

Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ.

Antimicrob Agents Chemother. 2004 Feb;48(2):437-43.

27.

Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ.

J Infect Dis. 2003 Oct 1;188(7):992-1000. Epub 2003 Sep 16.

PMID:
14513419
29.

Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.

Shulman NS, Hughes MD, Winters MA, Shafer RW, Zolopa AR, Hellmann NS, Bates M, Whitcomb JM, Katzenstein DA.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):121-7.

PMID:
12394789
30.

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.

Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, Deeks SG, Bates M, Hellmann NS, Petropoulos CJ.

AIDS. 2002 Oct 18;16(15):F41-7.

PMID:
12370521
31.

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.

Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D, McCutchan JA; California Collaborative Treatment Group.

AIDS. 2002 Oct 18;16(15):F33-40.

PMID:
12370520
32.

Antiretroviral-drug resistance among patients recently infected with HIV.

Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD.

N Engl J Med. 2002 Aug 8;347(6):385-94.

33.

Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates.

Duan C, Poticha D, Stoeckli TC, Petropoulos CJ, Whitcomb JM, McHenry CS, Kuritzkes DR.

J Infect Dis. 2001 Nov 15;184(10):1336-40. Epub 2001 Oct 15.

PMID:
11679926
34.

Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA.

Sarafianos SG, Das K, Tantillo C, Clark AD Jr, Ding J, Whitcomb JM, Boyer PL, Hughes SH, Arnold E.

EMBO J. 2001 Mar 15;20(6):1449-61.

35.

Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites.

Brown AJ, Precious HM, Whitcomb JM, Wong JK, Quigg M, Huang W, Daar ES, D'Aquila RT, Keiser PH, Connick E, Hellmann NS, Petropoulos CJ, Richman DD, Little SJ.

J Virol. 2000 Nov;74(22):10269-73.

36.

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM.

Antimicrob Agents Chemother. 2000 Apr;44(4):920-8.

37.

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.

Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD.

JAMA. 2000 Jan 12;283(2):229-34.

PMID:
10634339
38.

Reduced antiretroviral drug susceptibility among patients with primary HIV infection.

Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, Hellmann NS, Petropoulos CJ, Sutton L, Pitt JA, Rosenberg ES, Koup RA, Walker BD, Richman DD.

JAMA. 1999 Sep 22-29;282(12):1142-9.

PMID:
10501117
39.

The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors.

Schaefer-Klein J, Givol I, Barsov EV, Whitcomb JM, VanBrocklin M, Foster DN, Federspiel MJ, Hughes SH.

Virology. 1998 Sep 1;248(2):305-11.

41.
42.

A new PCR based method for the generation of nested deletions.

Whitcomb JM, Rashtchian A, Hughes SH.

Nucleic Acids Res. 1993 Aug 25;21(17):4143-6.

43.

Retroviral reverse transcription and integration: progress and problems.

Whitcomb JM, Hughes SH.

Annu Rev Cell Biol. 1992;8:275-306. Review. No abstract available.

PMID:
1282352
45.

Sequence of the circle junction of human immunodeficiency virus type 1: implications for reverse transcription and integration.

Whitcomb JM, Kumar R, Hughes SH.

J Virol. 1990 Oct;64(10):4903-6. Erratum in: J Virol 1990 Dec;64(12):6360.

46.

Dehydroepiandrosterone and structural analogs: a new class of cancer chemopreventive agents.

Schwartz AG, Whitcomb JM, Nyce JW, Lewbart ML, Pashko LL.

Adv Cancer Res. 1988;51:391-424. Review. No abstract available.

PMID:
2975913
47.

Inhibition of tumor development by dehydroepiandrosterone and related steroids.

Schwartz AG, Pashko L, Whitcomb JM.

Toxicol Pathol. 1986;14(3):357-62. Review.

PMID:
3024302
48.

Development of the spinal-medullary projection from the mouse barrel field.

Crandall JE, Whitcomb JM, Caviness VS Jr.

J Comp Neurol. 1985 Sep 8;239(2):205-15.

PMID:
4044935
50.

This new idea for the operating room wound reduce clutter-or would it.

JOHNSON EG, WHITCOMB JM.

Mod Hosp. 1957 Nov;89(5):52-3. No abstract available.

PMID:
13477199

Supplemental Content

Loading ...
Support Center